FINVASIA-GROUP
18.4.2022 10:32:08 CEST | Business Wire | Press release
Finvasia today announced that it has appointed Tajinder Virk as the interim Chief Executive Officer for ZuluTrade. He will replace the previous CEO from the company, effective immediately.
"Tajinder has been instrumental in building upon Finvaisa’s success and has an impressive track record in delivering growth for our group companies," said Sarvjeet Singh Virk, CMD & Co-founder Finvasia. "We have seen Tajinder (A.K.A. Natty) in action first hand and have the utmost confidence that his deep financial experience and leadership skills will drive results and accelerate ZuluTrade’s business in this interim role."
Tajinder Virk is the CEO of Finvasia Group of companies and is an exceptional leader with deep familiarity with all aspects of the business that allows him to develop and lead the execution of the group’s strategic vision, assess risks and guide the group’s growth. He has worked with some of the largest investment banks and hedge funds on Wall Street and has managed multibillion-dollar funds for major US banks, before co-founding Finvasia. At ZuluTrade, Tajinder will work closely with the team to deliver on the business expansion plan.
Commenting on the appointment, Tajinder said, “Finvasia is known for its innovative business approach and for its ability to create value for its clients. We see ZuluTrade as the largest Social Wealth Management platform that will bring more asset classes and industry participants together under a single platform.
“ZuluTrade is among the largest and the original social trading platforms that revolutionised copy trading in 2008. ZuluTrade 2.0 will maintain its legacy of being broker neutral, so it has no conflict of interest with its investors. We will be offering a variety of asset classes, encouraging more investors, leaders and brokers to join the platform whilst creating a conducive environment for them to grow their wealth,” he continued.
Finvasia’s board has simultaneously commenced a formal search for a permanent CEO for ZuluTrade who can deliver on the Group’s expectations for future ready products while maintaining its core values and cultures.
About ZULUTRADE (https://www.zulutrade.com )
ZuluTrade is the original social trading platform that revolutionised copy trading in 2008. It offers a massive database of Algo signals and strategies currently available across the market, catering to both advanced and novice investors alike.
It's a broker neutral platform that has catered to over 2.5 million clients in over 100 countries and supports over twenty-six languages.
About FINVASIA (https://finvasia.com )
Finvasia is a multi-disciplinary, multinational organisation that owns and operates over a dozen brands across financial services, technology, real estate and healthcare verticals.
Finvasia Group has managed funds for some of the notable hedge funds of Wall street, launched the first and only commission free ecosystem for financial products in India and is now aggressively expanding its presence in the European market. The Group has provided technology to some of the notable listed and unlisted financial services entities across the globe.
Furthermore, its healthcare division recently launched a medically proven diabetes reversal program in India and has engaged scientists from various specialised fields in an effort to build nano and micro medical devices that will cater to the future of medical engineering.
In the last 13 years, Finvasia has catered to a few million clients in over 180 countries directly or via its subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220418005251/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
